Overview

BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of BCX9930 monotherapy for the treatment of adult patients with PNH not currently receiving complement inhibitor therapy.
Phase:
Phase 2
Details
Lead Sponsor:
BioCryst Pharmaceuticals